Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Susceptibility of multiresistant gram-negative bacteria to fosfomycin and performance of different susceptibility testing methods.

Literature DB >> 24323469

Susceptibility of multiresistant gram-negative bacteria to fosfomycin and performance of different susceptibility testing methods.

L V Perdigão-Neto¹, M S Oliveira, C F Rizek, C M D M Carrilho, S F Costa, A S Levin.

Abstract

Fosfomycin may be a treatment option for multiresistant Gram-negative bacteria. This study compared susceptibility methods using 94 multiresistant clinical isolates. With agar dilution (AD), susceptibilities were 81%, 7%, 96%, and 100% (CLSI) and 0%, 0%, 96%, and 30% (EUCAST), respectively, for Acinetobacter baumannii, Pseudomonas aeruginosa, Klebsiella pneumoniae, and Enterobacter spp. Categorical agreement between Etest and AD for Enterobacteriaceae and A. baumannii was ≥80%. Disk diffusion was adequate only for Enterobacter. CLSI criteria for urine may be adequate for systemic infections.

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 2013 PMID： 24323469 PMCID： PMC3957874 DOI： 10.1128/AAC.02048-13

Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191

22 in total

Review 1. Emerging metallo-beta-lactamase-mediated resistances: a summary report from the worldwide SENTRY antimicrobial surveillance program.

Authors: Thomas R Fritsche; Helio S Sader; Mark A Toleman; Timothy R Walsh; Ronald N Jones
Journal: Clin Infect Dis Date: 2005-08-15 Impact factor: 9.079

2. In vitro activity of fosfomycin against blaKPC-containing Klebsiella pneumoniae isolates, including those nonsusceptible to tigecycline and/or colistin.

Authors: Andrea Endimiani; Gopi Patel; Kristine M Hujer; Mahesh Swaminathan; Federico Perez; Louis B Rice; Michael R Jacobs; Robert A Bonomo
Journal: Antimicrob Agents Chemother Date: 2009-11-09 Impact factor: 5.191

3. Detection of the Klebsiella pneumoniae carbapenemase type 2 Carbapenem-hydrolyzing enzyme in clinical isolates of Citrobacter freundii and K. oxytoca carrying a common plasmid.

Authors: J Kamile Rasheed; James W Biddle; Karen F Anderson; Laraine Washer; Carol Chenoweth; John Perrin; Duane W Newton; Jean B Patel
Journal: J Clin Microbiol Date: 2008-04-02 Impact factor: 5.948

4. High fosfomycin concentrations in bone and peripheral soft tissue in diabetic patients presenting with bacterial foot infection.

Authors: Michael V Schintler; Friederike Traunmüller; Julia Metzler; Gerhard Kreuzwirt; Stephan Spendel; Oliver Mauric; Martin Popovic; Erwin Scharnagl; Christian Joukhadar
Journal: J Antimicrob Chemother Date: 2009-07-03 Impact factor: 5.790

5. Disposition of phosphomycin in patients with pleural effusion.

Authors: C F Lastra; E L Mariño; M Barrueco; M S Gervós; A D Gil
Journal: Antimicrob Agents Chemother Date: 1984-04 Impact factor: 5.191

Review 6. Fosfomycin: use beyond urinary tract and gastrointestinal infections.

Authors: Matthew E Falagas; Konstantina P Giannopoulou; George N Kokolakis; Petros I Rafailidis
Journal: Clin Infect Dis Date: 2008-04-01 Impact factor: 9.079

7. Experience with fosfomycin for treatment of urinary tract infections due to multidrug-resistant organisms.

Authors: Elizabeth A Neuner; Jennifer Sekeres; Gerri S Hall; David van Duin
Journal: Antimicrob Agents Chemother Date: 2012-08-27 Impact factor: 5.191

Review 8. Clinical significance of the pharmacokinetic and pharmacodynamic characteristics of fosfomycin for the treatment of patients with systemic infections.

Authors: Nikos Roussos; Drosos E Karageorgopoulos; George Samonis; Matthew E Falagas
Journal: Int J Antimicrob Agents Date: 2009-10-13 Impact factor: 5.283

9. Susceptibility of urinary tract bacteria to fosfomycin.

Authors: Sofia Maraki; George Samonis; Petros I Rafailidis; Evridiki K Vouloumanou; Emmanuel Mavromanolakis; Matthew E Falagas
Journal: Antimicrob Agents Chemother Date: 2009-08-17 Impact factor: 5.191

10. Fosfomycin kinetics after intravenous and oral administration to human volunteers.

Authors: M Goto; M Sugiyama; S Nakajima; H Yamashina
Journal: Antimicrob Agents Chemother Date: 1981-09 Impact factor: 5.191

13 in total

Review 1. Fosfomycin: Resurgence of an old companion.

Authors: Sangeeta Sastry; Yohei Doi
Journal: J Infect Chemother Date: 2016-02-28 Impact factor: 2.211

2. Performance of Four Fosfomycin Susceptibility Testing Methods against an International Collection of Clinical Pseudomonas aeruginosa Isolates.

Authors: Elizabeth C Smith; Hunter V Brigman; Jadyn C Anderson; Christopher L Emery; Tiffany E Bias; Phillip J Bergen; Cornelia B Landersdorfer; Elizabeth B Hirsch
Journal: J Clin Microbiol Date: 2020-09-22 Impact factor: 5.948

Review 3. Fosfomycin.

Authors: Matthew E Falagas; Evridiki K Vouloumanou; George Samonis; Konstantinos Z Vardakas
Journal: Clin Microbiol Rev Date: 2016-04 Impact factor: 26.132

4. Use of Fosfomycin Etest To Determine In Vitro Susceptibility of Clinical Isolates of Enterobacterales Other than Escherichia coli, Nonfermenting Gram-Negative Bacilli, and Gram-Positive Cocci.

Authors: James A Karlowsky; Melanie R Baxter; Alyssa R Golden; Heather J Adam; Andrew Walkty; Philippe R S Lagacé-Wiens; George G Zhanel
Journal: J Clin Microbiol Date: 2021-09-08 Impact factor: 5.948

5. In Vitro Susceptibility of Multi-Drug Resistant Klebsiellapneumoniae Strains Causing Nosocomial Infections to Fosfomycin. A Comparison of Determination Methods.

Authors: Beata Mączyńska; Justyna Paleczny; Monika Oleksy-Wawrzyniak; Irena Choroszy-Król; Marzenna Bartoszewicz
Journal: Pathogens Date: 2021-04-23

6. Adverse Events Associated with Fosfomycin Use: Review of the Literature and Analyses of the FDA Adverse Event Reporting System Database.

Authors: Dmitri Iarikov; Ronald Wassel; John Farley; Sumathi Nambiar
Journal: Infect Dis Ther Date: 2015-10-05

7. The susceptibility to fosfomycin of Gram-negative bacteria isolates from urinary tract infection in the Czech Republic: data from a unicentric study.

Authors: Miroslav Fajfr; Miroslav Louda; Pavla Paterová; Lenka Ryšková; Jaroslav Pacovský; Josef Košina; Helena Žemličková; Miloš Broďák
Journal: BMC Urol Date: 2017-04-26 Impact factor: 2.264